GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » ROE % Adjusted to Book Value

Vivos (RDGL) ROE % Adjusted to Book Value : -10.65% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Vivos ROE % Adjusted to Book Value?

Vivos's ROE % for the quarter that ended in Dec. 2024 was -244.81%. Vivos's PB Ratio for the quarter that ended in Dec. 2024 was 22.98. Vivos's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -10.65%.

Vivos ROE % Adjusted to Book Value Historical Data

The historical data trend for Vivos's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos ROE % Adjusted to Book Value Chart

Vivos Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -15.91 -17.78 -10.58 -7.21

Vivos Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.86 -6.95 -2.72 -4.32 -10.65

Competitive Comparison of Vivos's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Vivos's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivos's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vivos's ROE % Adjusted to Book Value falls into.


;
;

Vivos ROE % Adjusted to Book Value Calculation

Vivos's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-165.72% / 22.98
=-7.21%

Vivos's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-244.81% / 22.98
=-10.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Vivos's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
HYPR ICAD ZOMDF VNRX OWLT PTHL APYX TELA NVNO CTSO ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
N/A
Address
719 Jadwin Avenue, Richland, WA, USA, 99352
Website
https://www.radiogel.com
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Executives
Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336